Pulished Date August, 2019
ID: 5798
Share on
Share on

Asia-Pacific Antibody Drug Conjugates Market By Pipeline Analysis (Phase, Mode Of Action [IgG1 Antibodies, HER2 Antibodies], Technology [Seattle Genetics, Immunogen, Immunomedics], Linker), End-user (Research Institutes, Hospitals, Clinics And Others) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts 2018-2023

Pulished: August, 2019
ID: 5798
Pages: 145

The Asia-Pacific Antibody Drug Conjugates Market was worth USD 1.52 billion in 2018 and estimated to be growing at a CAGR of 28.56%, to reach USD 5.34 billion by 2023. Antibody drug conjugate(ADC) is a biologically active drug used as targeted therapy in the treatment of cancer that is highly potent drugs of biopharmaceutical industry. These drugs are chemically complex molecules intended to kill the cancer cells in the body which composed of antibody that is biologically linked to anticancer drugs. These drugs target multiple pathways and reduces the risk of developing treatment resistant disorders in the body.

By the mechanism of action, the drugs are segmented into IgG1 antibodies and HER2 antibodies which affect different pathogens like bacteria, fungi and virus in the body. Antibody drug conjugates are widely accepting by several small and big pharmaceutical companies that is filling gaps between many oncology product pipelines. These drugs are also used in many other applications like metabolic disorders, cardiovascular, central nervous system, life science research tools, medical imaging and vaccines.

Factors like rise in cancer incidences, changing lifestyles, high investments by the companies in the pipeline analysis, cancer killing ability and research development of ADCs, growing biomedical industry, new product innovations and technology advancements are driving the Asia-Pacific Antibody Drug Conjugates Market. However, high cost of production of ADCs and stringent regulations for the product approval are hindering the growth of the market.

The Asia-Pacific Antibody Drug Conjugates Market is segmented on the basis of pipeline analysis, end-user and region. Based on the pipeline analysis, the market is segmented into phase, mode of action, technology and linker. The mode of action segment is sub-segmented into IgG1 antibodies and HER2 antibodies. The technology segment is further segmented into Seattle genetics, Immunogen and Immunomedics. On the basis of End-user, the market is segmented into research institutes, hospitals, clinics and others. The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Asia-Pacific is the fastest growing region with a high CAGR owing to the rise in prevalence of cancer, growing demographics and emerging economies like China and India.

Major companies dominating the Asia-Pacific Antibody Drug Conjugates Market are Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Pipeline Analysis                      

                                5.1.1 Introduction           

                                5.1.2 Phase        

                                5.1.3  Mode of action    

                                                5.1.3.1 IgG1 antibodies

                                                5.1.3.2 HER2 antibodies

                                5.1.4 Technology             

                                                5.1.4.1 Seattle Genetics

                                                5.1.4.2 Immunogen

                                                5.1.4.3 Immunomedics

                                5.1.5 Linker        

                                5.1.6 Y-o-Y Growth Analysis, By Pipeline Analysis              

                                5.1.7 Market Attractiveness Analysis, By Pipeline Analysis            

                                5.1.8 Market Share Analysis, By Pipeline Analysis             

                5.2 End-user                      

                                5.2.1 Introduction           

                                5.2.2 Research institutes              

                                5.2.3 Hospitals  

                                5.2.4 Clinics        

                                5.2.5 Others      

                                5.2.6 Y-o-Y Growth Analysis, By End-user             

                                5.2.7 Market Attractiveness Analysis, By End-user           

                                5.2.8 Market Share Analysis, By End-user             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Pipeline Analysis

                                                6.1.3.3 By End-user

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Pipeline Analysis

                                                6.1.4.3 By End-user

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Pipeline Analysis

                                                6.1.5.3 By End-user

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Seattle Genetics                       

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Genentech                 

                8.3 Takeda Pharmaceuticals                       

                8.4 F. Hoffmann-La Roche                           

                8.5 Bayer Healthcare                     

                8.6 Agensys, Inc.,                            

                8.7 Immunogen                               

                8.8 Novartis                       

                8.9 Oxford Biotherapeutics                         

                8.10 Synthon Biopharmaceuticals                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms Technology with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia Pacific Antibody Drug Conjugates  Market By Pipeline Analysis , From 2018-2023 ( USD Billion )
  2. Asia Pacific Phase Market By Region, From 2018-2023 ( USD Billion )
  3. Asia Pacific Mode of action Market By Region, From 2018-2023 ( USD Billion )
  4. Asia Pacific Technology Market By Region, From 2018-2023 ( USD Billion )
  5. Asia Pacific Linker Market By Region, From 2018-2023 ( USD Billion )
  6. Asia Pacific Antibody Drug Conjugates  Market By End-user , From 2018-2023 ( USD Billion )
  7. Asia Pacific Research institutes Market By Region, From 2018-2023 ( USD Billion )
  8. Asia Pacific Hospitals Market By Region, From 2018-2023 ( USD Billion )
  9. Asia Pacific Clinics Market By Region, From 2018-2023 ( USD Billion )
  10. Asia Pacific Others Market By Region, From 2018-2023 ( USD Billion )
  11. Japan Antibody Drug Conjugates  Market By Pipeline Analysis , From 2018-2023 ( USD Billion )
  12. Japan Antibody Drug Conjugates  Market By End-user , From 2018-2023 ( USD Billion )
  13. China Antibody Drug Conjugates  Market By Pipeline Analysis , From 2018-2023 ( USD Billion )
  14. China Antibody Drug Conjugates  Market By End-user , From 2018-2023 ( USD Billion )
  15. India Antibody Drug Conjugates  Market By Pipeline Analysis , From 2018-2023 ( USD Billion )
  16. India Antibody Drug Conjugates  Market By End-user , From 2018-2023 ( USD Billion )
  17. Australia Antibody Drug Conjugates  Market By Pipeline Analysis , From 2018-2023 ( USD Billion )
  18. Australia Antibody Drug Conjugates  Market By End-user , From 2018-2023 ( USD Billion )
  19. South Korea Antibody Drug Conjugates  Market By Pipeline Analysis , From 2018-2023 ( USD Billion )
  20. South Korea Antibody Drug Conjugates  Market By End-user , From 2018-2023 ( USD Billion )

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample